Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Ibeh, Bartholomew Okecuhukwu ^a   Omodamiro, Olushola D ^b   Ibeh, Urenna ^c   Habu, Josiah Bitrus ^a  

^a NATIONAL BIOTECHNOLOGY DEVELOPMENT AGENCY   (Nigeria)

^b MICHAEL OKPARA UNIVERSITY OF AGRICULTURE   (Nigeria)

^c HIV/AIDS/TB   (Nigeria)

Author keywords

ART; Biochemical; Haematological; HIV; Nigeria; Winniecure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMYLASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE; HEMOGLOBIN; HERBACEOUS AGENT; UNCLASSIFIED DRUG; UREA; WINNIECURE EXTRACT; PLANT EXTRACT;

ADOLESCENT; ADULT; ANALYZER; ANEMIA; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; EOSINOPHIL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRANULOCYTE; HEMATOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NIGERIA; PRIORITY JOURNAL; SPECTROPHOTOMETRY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD ANALYSIS; BLOOD EXAMINATION; KIDNEY FUNCTION TEST; MIDDLE AGED; PHYTOTHERAPY;

ADULT; ANTI-RETROVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; FEMALE; HEMATOLOGIC TESTS; HIV INFECTIONS; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NIGERIA; PHYTOTHERAPY; PLANT EXTRACTS; SPECTROPHOTOMETRY;

EID: 84884999896     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-73     Document Type: Article

References (54)

1. Federal Ministry of Health, HIV/syphilis seropositive science in Nigeria: technical report. AIDS/STDs Control Programme Government of Nigeria Abuja: Department of Public Health, Federal Ministry of Health 2004
2. Isolation spectrum of a T-lymphtropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Barre-sinoussi F, Chermann JC, Rey F, Sci 1983 220 868 871 10.1126/science.6189183 (Pubitemid 13080157)
3. Circulating coagulation inhibitors in the cquired immuno deficiency syndrome. Cohen AJ, Philips TM, Kesster CM, Ann Intern Med 1986 104 175 180 10.7326/0003-4819-104-2-175 3080933 (Pubitemid 16143681)
4. Hare CB, Pappalardo BL, Busch MP, Phelps P, Alexander SS, Ramstead C, Levy JA, Hecht FM, Negative HIV antibody test results among individuals treated with antiretroviral therapy (ART) during acute/early infection Bangkok: The proceedings of the XV International AIDS Conference 2004 11 16
5. Screening for HIV: a review of the evidence for the US preventive services task force. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT, Ann Intern Med 2005 143 1 55 73 10.7326/0003-4819-143-1-200507050-00010 15998755
6. Detection of human immunodeficiency virus type 1 infection by polymerase chain reaction in a cohort of seronegative intravenous drug users. Farzadegan H, Vlahov D, Solomon L, Muñoz A, Astemborski J, Taylor E, Burnley A, Nelson K, J Infect Dis 1993 168 2 327 331 10.1093/infdis/168.2.327 8335969 (Pubitemid 23210607)
7. HIV screening for all: the new standard of care. Armstrong WS, Taege AJ, Cleve Clin J Med 2007 74 4 297 301 10.3949/ccjm.74.4.297 17438679
8. AIDS patient care and STDs antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, Anzidei G, Fiscon M, Alberico S, Martinelli P, Placido G, Guaraldi G, Pinnetti C, Floridia M, AIDS Patient Care STDS 2009 23 7 513 520 10.1089/apc.2008.0263 19530956
9. Anti-HIV drug development-an overview. Pereira CF, Paridaen JT, Curr Pharm Des 2004 10 32 4005 4037 10.2174/1381612043382459 15579085 (Pubitemid 39654465)
10. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV outpatient study investigators. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, N Engl J Med 1998 338 13 853 860 10.1056/NEJM199803263381301 9516219 (Pubitemid 28135961)
11. United States Department of Health and Human Services, A pocket guide to adult HIV/AIDS treatment 2006 http://hab.hrsa.gov/deliverhivaidscare/files/ adultpcktguide06.pdf
12. Study confirms effectiveness of antiretroviral drugs for HIV patients. Anonymous, Lancet 2003 362 1267 1274 14575971
13. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. Farizo KM, Buchler JW, Ckhamberland ME, IDMA 1992 267 1798 1805
14. Haematological changes in adults receiving a zidovudinecontaining HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X, Antivir Ther 2005 10 5 615 624 16152755 (Pubitemid 41224953)
15. Haematologic effects of AIDS therapies. Pluda JM, Mitsuya H, Yarchoan R, Hematol Oncol Clin North Am 1991 5 229 248 1708759
16. Pathophysiology and management of HIV-associated haematologic disorders. Scadden DT, Zon LI, Groopman JE, Blood 1989 74 5 1455 1463 2676010 (Pubitemid 19251515)
17. Haematologic complication of HIV infection. Ellaine S, AIDS Rev 2005 7 4 187 196 16425959
18. Haematologic manifestations of the human immuno deficiency virus (HIV). Zon LI, Arkin C, Groompmau JE, B J Haemotol 1987 66 491 495 10.1111/j.1365-2141. 1987.tb01333.x
19. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial: the AIDS clinical trials group. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour HH, Spector SA, Volberding P, Pettinelli C, Anderson J, Ann Intern Med 1990 112 10 727 737 10.7326/0003-4819-112-10-727 1970466 (Pubitemid 20170211)
20. Calibration and validation for erythrocyte sedimentation tests. Thomas RD, Westengard JC, Hay KL, Bull BS, Arch Pathol Lab Med 1993 117 7 719 723 8323437
21. Measurement of direct bilirubin by use of bilirubin oxidase. Doumis BT, Perry B, Jendrzesczak B, Davis L, Clin Chem 1987 33 8 1349 1353 3608152 (Pubitemid 18041968)
22. Specific tropifm of HIV-1 for microghaceus in primary human brain culture. Watkins BA, Dom HH, Kelly WB, Sci 1990 249 4968 549 553 10.1126/science.2200125
23. Incidence and mechanism of neuropenia and thrombocytopenia in patients with HIV infection. Murphy MF, Metcalfe P, Water AH, Br J Haematol 1987 66 337 340 10.1111/j.1365-2141.1987.tb06920.x 3620353 (Pubitemid 17095293)
24. Assessment of liver and renal functions of asymtomatic human immuno deficiency virus (HIV)-seropositive individuals on winniecure (Herbal) therapy. Abdulahi JJ, Okoye MIJ, Agbonlahor E, Nwobu GO, Njab E, Ondobo RO, Ogieva OO, Amidi OG, Onoja AJ, J Med Lab Sci 2003 12 2 36 41
25. The effects of herbal extract (Winniecure) on CD + T-lymphocyte counts asymptomatic HIV-seropositive individuals. Agbonlabor D, Abdullahi JJ, Nwobu JO, Njab JE, Onodobo C, Ogieva O, Okoye MI, Onoja AJ, J Appl Basic Sci 2003 1 3 7
26. UNAIDS, UNAIDS report on the global AIDS epidemic 2010 http://www.unaids.org/globalreport/documents/20101123-GlobalReport-full-en.pdf
27. Joint United Nations Programme on HIV/AIDS (UNAIDS), AIDS epidemic update Geneva, Switzerland: UNAIDS 2007
28. United Nations Children's Fund, Young people and HIV/AIDS-opportunity in crisis New York, NY: 3 UN Plaza 2002 35 http://www.unicef.org/publications/ files/pub-youngpeople-hivaids-en.pdf
29. Health consequences of child marriage in Africa. Nawal MH, EID J 2006 12 11 1644 1649
30. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika W, Greenberg L, Allen S, Lancet 2008 371 2183 2191 10.1016/S0140-6736(08)60953-8 18586173 (Pubitemid 351885039)
31. Risk perception and condom-use among Thai youths: findings from Kanchanaburi demographic surveillance system site in Thailand. Haque MR, Soonthorndhada A, J Health Popul Nutr 2009 27 6 772 783 20099761
32. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD, AIDS 2010 24 12 1867 1876 10.1097/QAD.0b013e32833adbcf 20467286
33. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India. Rajasekaran S, Jeyaseelan L, Raja K, Vijila S, Krithigaipriya KA, Kuralmozhi R, J Postgrad Med 2009 55 4 261 266 10.4103/0022-3859.58929 20083872
34. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, Hogg R, Cooper C, AIDS 2011 25 6 851 855 10.1097/QAD.0b013e32834564e9 21330903
35. Leucopenia associated with lamotrigine. Nicholson RJ, Kelly KP, Grant IS, BMJ 1995 310 6978 504 7888894
36. Immunological nonresponse to highly active antiretroviral therapy in HIV-infected subjects: is the bone marrow impairment causing CD4 lymphopenia? Badolato R, CID 2008 46 2 1911 1912
37. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. Lacombe K, Pacanowski J, Meynard JL, Trylesinski A, Girard PM, AIDS 2005 19 10 1107 1108 10.1097/01.aids.0000174460.24171.0b 15958845 (Pubitemid 40961154)
38. CD4+ T-lymphopenia in HIV negative tuberculous patients at King Khalid University Hospital in Riyadh, Saudi Arabia. Al-Aska A, Al-Anazi AR, Al-Subaei SS, Al-Hedaithy MA, Barry MA, Somily AM, Buba F, Yusuf U, Al Anazi NA, Eur J Med Res 2011 16 6 285 288 10.1186/2047-783X-16-6-285 21810564
39. HIV gp120 alone may mediate lymphopenia and lymphadnopathy in HIV infected individuals. Green DS, Morgan R, Curcio-Bonner C, David CM, Cruikshank WW, J Immunol 2007 178 46.4
40. CD4 + lymphocyte cell enumeration for prediction of clinical course of human immuno deficiency virus disease: a review. Stein N, Korvick J, Vermunal SH, J Infect Dis 1992 165 352 363 10.1093/infdis/165.2.352 1346152
41. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. Baroncelli S, Pinnetti C, Genovese O, Tamburrini E, Floridia M, J Med Virol 2011 83 3 551 556 10.1002/jmv.21986 21264878
42. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, N Engl J Med 1987 317 192 197 10.1056/NEJM198707233170402 3299090 (Pubitemid 17103099)
43. Tierney LM, Mcphee SJ, Paadlcis MA, Current medical diagnosis and treatment New York USA: Lange Medical Books/McGraw-Hill 40 2001
44. Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. Asgeir J, Ezra N, Svein GG, Johan NB, BMC Infect Dises 2011 11 190 199 10.1186/1471-2334-11-190
45. Molecular classification and pathogenesis of eosinophilic disorders. Gotlib J, Acta Haematol 2005 114 1 7 25 10.1159/000085559 15995322 (Pubitemid 40911569)
46. Relation between erythrocyte sedimentation rate, clinical and immune status in HIV infected patients. Ndakotsu MA, Salawu L, Durosinmi MA, Nig J Med 2008 17 4 420 422
47. Hemophagocytic syndrome after highly active antiretroviral therapy initiation: a life-threatening event related to immune restoration inflammatory syndrome? Cuttelod M, Pascual A, Baur Chaubert AS, et al. AIDS 2008 22 4 549 551 10.1097/QAD.0b013e3282f4a0fd 18301077 (Pubitemid 351317306)
48. Lamivudine associated macrocytosis in HIV infected patients. Khawcharoenporn T, Shikuma CM, Williams AE, Chow DC, Int J STD AIDS 2007 18 39 40 10.1258/095646207779949934 17326861
49. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency: a report from the multicenter AIDS cohort study. Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, Polk BF, Blackwelder W, Ann Intern Med 1987 107 474 480 10.7326/0003-4819-107-4- 474 2957944 (Pubitemid 17149761)
50. Hemorrhagic disorders: abnormalities of platelet and vascular function. McMillan R, Cecil medicine Philadelphia, Pa: Saunders Elsevier, Goldman L, Ausiello D, 23 2007
51. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, J Acquir Immune Defic Syndr 2006 43 27 34 10.1097/01.qai.0000233310.90484.16 16878047 (Pubitemid 44306484)
52. TDCoAEoA-HIVdS: factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Smith C, Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, AIDS 2010 24 1537 1548 20453631
53. Influence of antiretroviral therapy on liver disease. Kovar H, Weber R, Curr Opin HIV AIDS 2011 6 4 272 277 10.1097/COH.0b013e3283473405 21508839
54. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Sulkowski MS, Clin Infect Dis 2004 38 S 2 90 S97 14986280